A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

2020 ◽  
Author(s):  
Anca Chelariu-Raicu ◽  
Alpa Nick ◽  
Renata Urban ◽  
Mary Gordinier ◽  
Carola Leuschner ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Open Label ◽  
Randomized Phase Ii ◽  
Lhrh Receptor

scholarly journals A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

2019 ◽  
Vol 26 (5) ◽  
pp. 1009-1016 ◽  
Author(s):  
Amit M. Oza ◽  
Ursula A. Matulonis ◽  
Angeles Alvarez Secord ◽  
John Nemunaitis ◽  
Lynda D. Roman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Resistant ◽  
Randomized Phase Ii

scholarly journals Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)

PLoS ONE ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. e0235381 ◽  
Author(s):  
Izabella Picinin Safe ◽  
Marcus Vinícius Guimarães Lacerda ◽  
Vitoria Silva Printes ◽  
Adriana Ferreira Praia Marins ◽  
Amanda Lia Rebelo Rabelo ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Hospitalized Patients ◽  
Open Label ◽  
Safety And Efficacy ◽  
Randomized Phase Ii

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

2004 ◽  
Vol 54 (4) ◽  
pp. 283-289 ◽  
Author(s):  
Robert J. Morgan ◽  
Timothy W. Synold ◽  
David Gandara ◽  
Franco Muggia ◽  
Sidney Scudder ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Resistant

scholarly journals Delta tocotrienol in recurrent ovarian cancer. A phase II trial

2019 ◽  
Vol 141 ◽  
pp. 392-396 ◽  
Author(s):  
Caroline Brenner Thomsen ◽  
Rikke Fredslund Andersen ◽  
Karina Dahl Steffensen ◽  
Parvin Adimi ◽  
Anders Jakobsen
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer

scholarly journals Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

2020 ◽  
Vol 159 (1) ◽  
pp. 88-94
Author(s):  
Jung-Min Lee ◽  
Christina M. Annunziata ◽  
John L. Hays ◽  
Liang Cao ◽  
Peter Choyke ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Bevacizumab Treatment

scholarly journals A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer

2020 ◽  
Vol 26 (18) ◽  
pp. 4767-4776 ◽  
Author(s):  
Amit M. Oza ◽  
Maria Estevez-Diz ◽  
Eva-Maria Grischke ◽  
Marcia Hall ◽  
Frederik Marmé ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Platinum Sensitive ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document